Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinibFuminori Takahashi, Shyamala Maheswaran, Naokazu Chiba et al.|Oncogene|2011Cited by 66